Neoplasms

Digestive System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Stomach Neoplasms

Recurrence

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Pharmaceutical Solutions

All Drugs and Chemicals

Antineoplastic Agents

Fluorouracil

Mitomycins

Mitomycin

curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1

curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1

surgery

adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)

adjuvant systemic chemotherapy

operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2

1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq

Early postoperative intraperitoneal chemothgerapy

Wansik Yu, MD, PhD, FACS

Wansik Yu, MD, PhD

Oh Kyoung Kwon, MD

Wansik Yu, MD. PhD

Intraperitoneal chemotherapy as an adjuvant treatment modality is designed to eradicate intraperitoneal free tumor cells that can be a source of peritoneal carcinomatosis. Although we have not reached unanimous consensus, favorable reports on the outcome of intraperitoneal chemotherapy have been published.

In this study, we review the clinicopathological characteristics of patients and effects of early postoperative intraperitoneal chemotherapy (EPIC) on overall and gastric cancer-specific survival and patterns of recurrence of gastric cancer patients with macroscopic serosal invasion.

The aim of this study is to evaluate the impact of intraperitoneal chemotherapy on overall and disease free survival of advanced gastric cancer patients with serosal invasion after potentially curative surgery.

Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer

Prospective Randomized Multicenter Phase III Trial of Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer

In hospital complication related to surgery or intraperitoneal chemotherapy will be recored and analyzed to evaluate the safety of intraperitoneal chemotherapy.

during regular follow-up with blood test, radiologic, endoscopic surveillance patients with recurrence will be detected and recorded

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer	NCT02205008	Advanced Gastri...	surgery adjuvant system... Early postopera...	19 Years - 70 Years	Kyungpook National University Hospital
Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer	NCT02205008	Advanced Gastri...	surgery adjuvant system... Early postopera...	19 Years - 70 Years	Kyungpook National University Hospital

Spots Global Cancer Trial Database for advanced gastric cancer with serosal invasion